SINBAD

SINBAD evaluates whether Mirtazapine or Carbamazepine are more effective than placebo in treating agitation in people with dementia. The trial will assess the safety, clinical and cost effectiveness of each treatment. Participants will be randomised to receive one of the treatments for 12 weeks and will be followed up for up to one year, in this blinded trial.
Currently Hoveton and Wroxham Medical Centre are taking part. If you are registered at Hoveton and Wroxham, please speak to your GP for more information.
Comments